Korea Exchange · Healthcare
Dongwha Pharm.Co. stock from India: price, numbers and tax
Dongwha Pharm.Co. (000020) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Dongwha Pharm.Co. at a glance
- Price
- ₩5,360.00-₩250.00 (4.46%)
- Market cap
- ₩148.57B
- Day range
- ₩5,340.00 – ₩5,510.00
- P/E
- 8.21
- Dividend yield
- 4.57%
- Volume
- 371.91K
- 1 month
- +4.28%
- 6 months
- -8.84%
- YTD
- -14.24%
- 1 year
- -15.72%
- 5 years
- -72.30%
Dongwha Pharm.Co. statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩496.4B | ₩464.9B | ₩361.1B | ₩340.4B | ₩293.0B |
| Gross profit | ₩203.3B | ₩214.3B | ₩190.4B | ₩181.0B | ₩149.3B |
| Operating income | −₩809.2M | ₩13.4B | ₩25.3B | ₩29.9B | ₩22.5B |
| Net income | ₩8.7B | ₩5.6B | ₩27.4B | ₩20.4B | ₩17.9B |
| Earnings per share | ₩313.37 | ₩200.71 | ₩991.07 | ₩736.42 | ₩646.68 |
| EBITDA | ₩21.2B | ₩28.7B | ₩48.7B | ₩38.2B | ₩39.4B |
| Total assets | ₩642.2B | ₩619.6B | ₩565.0B | ₩461.1B | ₩447.8B |
| Total debt | ₩118.4B | ₩97.0B | ₩47.1B | ₩6.7B | ₩11.5B |
| Cash and short-term investments | ₩24.3B | ₩43.5B | ₩88.8B | ₩107.7B | ₩121.5B |
| Shareholders' equity | ₩379.5B | ₩373.4B | ₩371.8B | ₩364.4B | ₩346.9B |
| Operating cash flow | ₩15.7B | −₩4.0B | ₩29.2B | ₩29.2B | ₩36.0B |
| Free cash flow | −₩37.5B | −₩78.1B | ₩2.8B | ₩9.1B | ₩11.3B |
| Capital expenditure | −₩53.2B | −₩74.1B | −₩26.3B | −₩20.1B | −₩24.8B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Yuhan | 000100.KS | ₩73,100.00 | ₩5.38T |
| Dong-A Socio | 000640.KS | ₩93,000.00 | ₩626.13B |
| Hyundai Pharmaceutical | 004310.KS | ₩7,760.00 | ₩181.97B |
| SAMSUNG PHARM. | 001360.KS | ₩1,376.00 | ₩129.51B |
| Ildong | 000230.KS | ₩6,160.00 | ₩71.09B |
| Yuyu Pharma | 000220.KS | ₩3,840.00 | ₩60.47B |
| China Resources Sanjiu Medical & Pharmaceutical | 000999.SZ | $24.82 | $41.31B |
| Dong-E-E-Jiao | 000423.SZ | $46.68 | $29.87B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Dongwha Pharm.Co. from India
What Dongwha Pharm.Co. does
Dongwha Pharm Co., Ltd. is a South Korean entity primarily engaged in the production and distribution of pharmaceutical goods. The company's diverse offerings include prescription-only medications addressing a wide spectrum of health concerns such as digestive and infectious diseases, cardiovascular and metabolic disorders, inflammatory and respiratory conditions, musculoskeletal and neurological ailments, as well as dermatological and urological issues. Dongwha Pharm.Co. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Dongwha Pharm.Co. shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.